Journal article
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane
Abstract
PURPOSE: Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
PATIENTS AND METHODS: …
Authors
Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH; Clavell LA; Larsen EC; Moghrabi A; Samson Y
Journal
Journal of Clinical Oncology, Vol. 26, No. 7, pp. 1106–1111
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2008
DOI
10.1200/jco.2007.12.2481
ISSN
0732-183X